Gilead Sciences has expanded into the in vivo cell therapy arena by acquiring Interius BioTherapeutics for $350 million. This acquisition grants Gilead a technology platform capable of genetically modifying immune cells within the body, representing a shift from ex vivo CAR-T cell therapies. The deal places Gilead alongside AstraZeneca and AbbVie in pursuing more scalable and accessible cell-based cancer therapies. Interius's single-shot CAR-T program, aimed at simplifying treatment, complements Gilead's Kite Pharma subsidiary's existing cancer cell therapy portfolio.